看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。( Q* o1 t+ m+ c5 w z+ E+ i0 u
& L( f* V3 X2 ?$ |( O
* u8 F- f& o. h$ T
Currently available feasibility data for possible combination strategies. 8 s( U/ e& k# d1 t# _
————————————————————————————————+ ]$ Q: S$ q9 q1 v# p2 O+ S# @/ k
Combination Feasibility according to preliminary data
# D( f+ W* ?- \: W' ^——————————————————————————————————
' x- u K$ S" J" |3 h3 w' yBevacizumab + sorafenib Yes, reduced dose
$ I( K; U5 Y7 |Bevacizumab + sunitinib† No 1 E# ~5 K0 Q0 X0 O3 T8 `
Bevacizumab + temsirolimus Yes 2 _0 _1 m& {$ q- N+ X ~0 J% n
Bevacizumab + everolimus Yes / A5 T! E H+ U+ T0 u
Sorafenib + sunitinib ?
( k$ T( u$ S6 T7 h) ]Sorafenib + temsirolimus Yes, reduced dose & Q2 K* t F! Z0 \1 m* ]
Sorafenib + everolimus Yes, reduced dose 0 i! {3 X. B# G2 `
Sunitinib + temsirolimus† No
& f8 v3 a* p) i5 J+ z; BSunitinib + everolimus ? # K- @3 m4 Y# R
Temsirolimus + everolimus ?
" G& J& ~8 N. M1 \5 u+ j& H+ I$ b. ] V————————————————————& u: w4 { e; ]" R% A
†Led to US FDA warning.; E; t. Y; ?; K' V; {: i1 w
?: As yet unattempted combination.
s5 B! H) t) [' | |